Outcomes of Differentiated Models of Antiretroviral Treatment (ART) Provision

HIV/AIDS Clinical Trial

— [MMD]  

Official title:

Outcomes of Differentiated Models of Antiretroviral Treatment (ART) Provision: Multi-Month Dispensing (MMD) of ART in Community ART Distribution for Stable HIV Infected Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03438370
• Other study ID #: ID49-2017
• Status: Recruiting
• Phase: N/A
• First received: August 1, 2017
• Last updated: February 16, 2018
• Start date: August 7, 2017
• Est. completion date: September 2019

Study information

• Verified date: August 2017
• Source: Equip, Lesotho
• Contact: Iyiola Faturiyele, MBChB, MPH
• Phone: 00266 5939 9691
• Email: Iyiola.Faturiyele[@]equiphealth.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evalulate the effectiveness and cost-effectiveness of three models of ART provision for stable ART patients. The objectives are to measure patient retention, virological suppression, provider and patient costs, cost-effectiveness, and patient acceptability amongst stable patients who receive ART at intervals of three and six months within community distribution models, and to compare these to patients who receive ART directly from the clinic at three month intervals.

Methods

A prospective, parallel, cluster-randomized non-inferiority trial with three study arms will be conducted. 30 Clusters (sites) will be randomized in strata according to geographic location (urban and rural) to the 3 study arms as follows:

• Control arm: sites at which patients will receive three monthly ART supply at the facility (arm 3MF).

• Intervention arm 1: sites at which patients will receive three monthly ART supply in CAGs (arm 3MC)

• Intervention arm 2: sites at which patients will receive six monthly ART supply in the community by a healthcare worker (arm 6MCD).

The study population will consist of stable, HIV-infected adults who have received first-line ART for at least six months, who have a viral load <1000 copies/ml at baseline, and who provide informed consent for inclusion in the study. An average of 192 participants from each study site will be included, with a total sample size of approximately 5760 participants.

The primary outcome is retention in care defined as the proportion of patients remaining in care 12 months after study enrolment, with the hypothesis that patient retention within the intervention arms will be non-inferior compared to the control arm. Retention in care will also be compared between the three arms after 24 months.

The secondary outcomes are:

• Viral suppression: defined as the proportion of patients with virological suppression (<1000 copies/ml) 12 and 24 months after study enrolment;

• Cost of providing ART: defined as the cost per patient of providing ART in each of the three arms (from a provider perspective);

• Cost of retaining a patient: defined as the provider cost per patient retained and provider cost per patient retained with virological suppression in each of the three arms, and the incremental cost-effectiveness ratio for the comparative arms.

Description:

Background In 2015, sub-Saharan Africa was still the region most affected by the HIV epidemic, with 25.6 (23.1-28.5) million people living with HIV in 2015. It is estimated that 42% of all people living with HIV (PLHIV) in Lesotho were receiving ART by 2015.The United States Government's President's Emergency Plan for AIDS Relief (PEPFAR) has adopted the goals of 90-90-90 from UNAIDS, and is supporting a swift implementation of the new World Health Organization'sTest and Start guidelines.With these goals, PEPFAR also sets out to reduce new infections by 75% and to attain zero discrimination and stigma for all PLHIV.

To assist countries to reach the goal of universal coverage, EQUIP Innovation for health (a new field support award from the USAID Office of HIV and AIDS that supports innovations in HIV clinical and community-based HIV treatment related services) is evaluating communitybased care, treatment and support models to create an enabling environment for massive scale-up of ART delivery and adherence support. Based on this background, EQUIP and and Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) propose to conduct operational research that seeks to understand and measure the effectiveness of implementing a package of services that include multi-month dispensing (MMD) of ART drugs, Community ART distribution models through Community ART Groups (CAGs) and Community Distribution points and routine viral load monitoring of stable patients in communities of PEPFAR/USAID Lesotho scale-up districts.

The aim of this study is to evalulate the effectiveness and cost-effectiveness of three models of ART provision for stable ART patients. The objectives are to measure patient retention, virological suppression, provider and patient costs, cost-effectiveness, and patient acceptability amongst stable patients who receive ART at intervals of three and six months within community distribution models, and to compare these to patients who receive ART directly from the clinic at three month intervals.

Methods

A prospective, parallel, cluster-randomized non-inferiority trial with three study arms will be conducted. 30 Clusters (sites) will be randomized in strata according to geographic location (urban and rural) to the 3 study arms as follows:

• Control arm: sites at which patients will receive three monthly ART supply at the facility (arm 3MF).

• Intervention arm 1: sites at which patients will receive three monthly ART supply in CAGs (arm 3MC)

• Intervention arm 2: sites at which patients will receive six monthly ART supply in the community by a healthcare worker (arm 6MCD).

Sites for inclusion in the study will be selected at which it is deemed to be feasible to implement multi-month dispensing of ART in the community.

The study population will consist of stable, HIV-infected adults who have received first-line ART for at least six months, who have a viral load <1000 copies/ml at baseline, and who provide informed consent for inclusion in the study. An average of 192 participants from each study site will be included, with a total sample size of approximately 5760 participants. For those sites randomized to the 3MC arm, enrolled participants will be part of a CAG for the duration of the study. For those sites randomized to the 6MCD arm, enrolled participants will be dispensed a 6-month supply of ART in the community by a healthcare worker in between their annual clinical assessments. All participants will have a clinical assessment and viral load testing at the clinic at least annually, and participants will be followed-up for 24 months after enrolment.

The primary outcome is retention in care defined as the proportion of patients remaining in care 12 months after study enrolment, with the hypothesis that patient retention within the intervention arms will be non-inferior compared to the control arm. Retention in care will also be compared between the three arms after 24 months.

The secondary outcomes are:

• Viral suppression: defined as the proportion of patients with virological suppression (<1000 copies/ml) 12 and 24 months after study enrolment;

• Cost of providing ART: defined as the cost per patient of providing ART in each of the three arms (from a provider perspective);

• Cost of retaining a patient: defined as the provider cost per patient retained and provider cost per patient retained with virological suppression in each of the three arms, and the incremental cost-effectiveness ratio for the comparative arms.

Qualitative research will include assessing the acceptability of multi-month dispensing of ART within CAGs and the community from both a patient and healthcare provider perspective. Costs to patients will be compared between the three arms from data derived from patient surveys. In addition, indicators of potential facility level decongestion will be compared between arms, which will include the median facility patient waiting time and average monthly number of patients newly initiated on ART, with data derived from site surveys and routine facility-level data.

This study will follow the ethical considerations specified by the Lesotho National Health Research and Ethics Committee.

The results of the study are expected to inform health policy both nationally and regionally regarding the effectiveness of implementing a package of services consisting of MMD within CAGs and community distribution together with viral load monitoring for stable ART patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5760
• Est. completion date: September 2019
• Est. primary completion date: August 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• At least 18 years of age and willing and able to provide written informed consent for participation in this study.

• Willing to participate in the multi-month dispensing model that the patient's study site has been randomized to.

• On ART = 6 months with no periods of defaulting from ART since the last viral load result (ART default defined as missing 7 or more consecutive days of ART)

• On first-line ART regimen (substitutions within the first-line regimen prior to the last viral load test are permissible).

• No ARV drug substitutions since the last viral load result < 1,000 copies per ml

• Plasma or dried-blood spot viral load < 1,000 copies/ml in a patient who has been on first-line ART for at least 6 months, with viral load drawn within last 12 months of enrollment while patient is receiving ART

Exclusion Criteria:

• On second-line ART regimen.

• Patients with co-morbidities requiring facility visits more often than 6 monthly.

• ART substitutions since last VL test.

• Diagnosed with a WHO clinical stage 3 or 4 condition within the past 3 months.

• Pregnant or less than 12 months postpartum and breastfeeding mothers.

• Participating in another study that involves dispensing interval, adherence, or retention or involves receiving medications.

Related Conditions & MeSH terms

• HIV/AIDS

Intervention

Other:
• Three monthly ART supply at CAGs
Sites where three monthly ART supply will be provided at outreaches
• Six monthly ART supply at outreaches
Sites where six monthly ART will supply will be provided at outreaches

Locations

Country	Name	City	State
Lesotho	Ha Tlali	Maseru

Sponsors (7)

Lead Sponsor	Collaborator
Equip, Lesotho	Chemonics, Elizabeth Glaser Pediatric AIDS Foundation, Lesotho Network of AIDS Services Organizations, Ministry of Health, Lesotho, National Drugs Service Organisation of Lesotho, United States Agency for International Development (USAID)

Country where clinical trial is conducted

Lesotho, 

References & Publications (34)

Amanyire G, Wanyenze R, Alamo S, Kwarisiima D, Sunday P, Sebikaari G, Kamya M, Wabwire-Mangen F, Wagner G. Client and provider perspectives of the efficiency and quality of care in the context of rapid scale-up of antiretroviral therapy. AIDS Patient Care — View Citation

Ammassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: the role of adherence in the late HAART era. Antivir Ther. 2012;17(5):785-92. doi: 10.3851/IMP2084. Epub 2012 Mar 13. Review. — View Citation

Bemelmans M, Baert S, Goemaere E, Wilkinson L, Vandendyck M, van Cutsem G, Silva C, Perry S, Szumilin E, Gerstenhaber R, Kalenga L, Biot M, Ford N. Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health. — View Citation

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, et al., editors. Final results of the HPTN 052 randomized controlled trial: antiretroviral therapy prevents HIV transmission. Journal of the International AIDS Society; 2015: INT AIDS SO

Coker M, Etiebet MA, Chang H, Awwal G, Jumare J, Musa BM, Babashani M, Habib AG, Dakum P, Abimiku AG, Charurat ME, Blattner WA, Eng M, Ndembi N. Socio-Demographic and Adherence Factors Associated with Viral Load Suppression in HIV-Infected Adults Initiati — View Citation

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd edition. Geneva: World Health Organization; 2016. — View Citation

Decroo T, Koole O, Remartinez D, dos Santos N, Dezembro S, Jofrisse M, Rasschaert F, Biot M, Laga M. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop Med Int Health. 2014 May;19(5):514-21. — View Citation

Fairall L, Bachmann MO, Lombard C, Timmerman V, Uebel K, Zwarenstein M, Boulle A, Georgeu D, Colvin CJ, Lewin S, Faris G, Cornick R, Draper B, Tshabalala M, Kotze E, van Vuuren C, Steyn D, Chapman R, Bateman E. Task shifting of antiretroviral treatment fr — View Citation

Fatti G, Shaikh N, Eley B, Grimwood A. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: a multicentre cohort study from South Africa. AIDS Care. 2014 Apr;26(4):448-53. doi: 10.1080/09540 — View Citation

Fay H, Baral SD, Trapence G, Motimedi F, Umar E, Iipinge S, Dausab F, Wirtz A, Beyrer C. Stigma, health care access, and HIV knowledge among men who have sex with men in Malawi, Namibia, and Botswana. AIDS Behav. 2011 Aug;15(6):1088-97. doi: 10.1007/s1046 — View Citation

Ferrand RA, Briggs D, Ferguson J, Penazzato M, Armstrong A, MacPherson P, Ross DA, Kranzer K. Viral suppression in adolescents on antiretroviral treatment: review of the literature and critical appraisal of methodological challenges. Trop Med Int Health. — View Citation

Geng EH, Glidden DV, Emenyonu N, Musinguzi N, Bwana MB, Neilands TB, Muyindike W, Yiannoutsos CT, Deeks SG, Bangsberg DR, Martin JN. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infect — View Citation

Government of Lesotho. National guidelines on the use of antiretroviral therapy for HIV prevention and treatment. In: MOH, editor.2014

Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. Geneva: World Health Organization; 2015 Sep. — View Citation

Joint United Nations Programme on HIV/AIDS (UNAIDS). COMMUNITY-BASED ANTIRETROVIRAL THERAPY DELIVERY. EXPERIENCES OF MÉDECINS SANS FRONTIÈRES. 2015.

Joint United Nations Programme on HIV/AIDS. AIDS by numbers2016.

Lake S, Kammann E, Klar N, Betensky R. Sample size re-estimation in cluster randomization trials. Stat Med. 2002 May 30;21(10):1337-50. — View Citation

Lesotho Go. Lesotho CAG toolkit In: MOH, editor.2015.

Loeliger KB, Niccolai LM, Mtungwa LN, Moll A, Shenoi SV. Antiretroviral therapy initiation and adherence in rural South Africa: community health workers' perspectives on barriers and facilitators. AIDS Care. 2016 Aug;28(8):982-93. doi: 10.1080/09540121.20 — View Citation

Marconi VC, Wu B, Hampton J, Ordóñez CE, Johnson BA, Singh D, John S, Gordon M, Hare A, Murphy R, Nachega J, Kuritzkes DR, del Rio C, Sunpath H; South Africa Resistance Cohort Study Team Group Authors. Early warning indicators for first-line virologic fai — View Citation

McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ. 2013 May 1;91(5):377-385E. doi: 10.2471/BLT.12.11294 — View Citation

MOH Lesotho. GLOBAL AIDS RESPONSE PROGRESS REPORT 2015. 2015 Reporting Period: January - December 2014.

Ndahimana Jd, Riedel DJ, Mwumvaneza M, Sebuhoro D, Uwimbabazi JC, Kubwimana M, Mugabo J, Mulindabigwi A, Kirk C, Kanters S, Forrest JI, Jagodzinski LL, Peel SA, Ribakare M, Redfield RR, Nsanzimana S. Drug resistance mutations after the first 12 months on — View Citation

Rasschaert F, Decroo T, Remartinez D, Telfer B, Lessitala F, Biot M, Candrinho B, Van Damme W. Sustainability of a community-based anti-retroviral care delivery model - a qualitative research study in Tete, Mozambique. J Int AIDS Soc. 2014 Oct 6;17:18910. — View Citation

Rollins NC, Becquet R, Orne-Gliemann J, Phiri S, Hayashi C, Baller A, Shaffer N; INSPIRE Team. Defining and analyzing retention-in-care among pregnant and breastfeeding HIV-infected women: unpacking the data to interpret and improve PMTCT outcomes. J Acqu — View Citation

Roy M, Czaicki N, Holmes C, Chavan S, Tsitsi A, Odeny T, Sikazwe I, Padian N, Geng E. Understanding Sustained Retention in HIV/AIDS Care and Treatment: a Synthetic Review. Curr HIV/AIDS Rep. 2016 Jun;13(3):177-85. doi: 10.1007/s11904-016-0317-9. Review. — View Citation

Scott CA, Iyer H, Bwalya DL, McCoy K, Meyer-Rath G, Moyo C, Bolton-Moore C, Larson B, Rosen S. Retention in care and outpatient costs for children receiving antiretroviral therapy in Zambia: a retrospective cohort analysis. PLoS One. 2013 Jun 28;8(6):e679 — View Citation

Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013;18(1):115-23. doi: 10.3851/IMP2437. Epub 2012 Oct 10. Review. — View Citation

Teck R. Reducing frequency of ARV pick-ups for HIV patients stabilised on ARV treatment 2015.

Tiruneh YM, Galárraga O, Genberg B, Wilson IB. Retention in Care among HIV-Infected Adults in Ethiopia, 2005- 2011: A Mixed-Methods Study. PLoS One. 2016 Jun 7;11(6):e0156619. doi: 10.1371/journal.pone.0156619. eCollection 2016. — View Citation

Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2010 Aug;14(4):778-84. doi: 10.1007/s1 — View Citation

WHO. HIV/AIDS: Fact sheet. 2016 [cited 2016 12/12/2016].

World Health Organization. Retention in HIV programmes: defining the challenges and identifying solutions: meeting report, 13-15 September 2011. 2012.

Xu X, Grossetta Nardini HK, Ruger JP. Micro-costing studies in the health and medical literature: protocol for a systematic review. Syst Rev. 2014 May 21;3:47. doi: 10.1186/2046-4053-3-47. Review. — View Citation

* Note: There are 34 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	retention in care	The proportion of patients remaining in care 12 months after study enrolment	12 months
Secondary	Viral suppression	The proportion of patients with virological suppression (<1000 copies/ml) 12 months after study enrolment	12 months
Secondary	Cost of providing ART	The cost per patient of providing ART in each of the three arms (from a provider perspective)	12 months
Secondary	Cost of retaining a patient	The provider cost per patient retained and provider cost per patient retained with virological suppression in each of the three arms	12 months

External Links

•   UNAIDS. Lesotho: HIV and AIDS estimates.